Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Sales reflect continued strong growth in oncology and vaccines
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Combination shows consistent benefit across prespecified post-progression outcomes
Subscribe To Our Newsletter & Stay Updated
